FDA advisers vote 6-4 that GRAIL's Galleri blood test is effective, 7-2 that benefits outweigh risks

The FDA's Molecular and Clinical Genetics Panel voted 6-4 that GRAIL's Galleri multicancer blood test is effective for its proposed use and 7-2, with one abstention, that its benefits outweigh its risks. Medicare coverage could follow FDA approval; GRAIL shares had jumped about 35% to $109.18 ahead of the meeting.

Detected & updated continuously · Source: Nebula